CLAIMS

WHAT IS CLAIMED:

1. A pyrrole substituted 2-indolinone having the chemical structure:



wherein:

R^1 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, hydroxy, alkoxy, C-carboxy, O-carboxy, acetyl, C-amido, C-thioamido, sulfonyl and trihalomethanesulfonyl;

R^2 is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl and heteroalicyclic;

R^3, R^4, R^5 and R^6 are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, trihalomethane-sulfonamido, carbonyl, C-carboxy, O-carboxy, C-amido, N-amido, cyano, nitro, halo, O-

carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, amino and $-NR^{11}R^{12}$;

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, carbonyl, acetyl, sulfonyl, trifluoromethanesulfonyl and, combined, a five- or six-member heteroalicyclic ring;

R^3 and R^4, R^4 and R^5, or R^4 and R^5 may combine to form a six-member aryl ring, a methylenedioxy group or an ethylenedioxy group;

R^7 is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, carbonyl, acetyl, C-amido, C-thioamido, amidino, C-carboxy, O-carboxy, sulfonyl and trihalomethane-sulfonyl;

R^8, R^9 and R^{10} are independently selected from the group consisting of hydrogen, alkyl, trihaloalkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy, mercapto, alkylthio, arylthio, sulfinyl, sulfonyl, S-sulfonamido, N-sulfonamido, carbonyl, C-carboxy, O-carboxy, cyano, nitro, halo, O-carbamyl, N-carbamyl, O-thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, amino and $-NR^{11}R^{12}$, providing, however, that at least one of R^8, R^9 or R^{10} is a group having the formula $-(alk_1)Z$ wherein:

Alk_1 is selected from the group consisting of alkyl, alkenyl or alkynyl; and,

Z is a polar group.

2. The compound of claim 1 wherein R^1 R^2 and R^7 are hydrogen.

3. The compound of claim 2 wherein one of R^8, R^9 or R^{10} is alk_1Z wherein:

alk_1 is selected from the group consisting of unsubstituted lower alkyl, unsubstituted lower alkenyl and unsubstituted lower alkynyl; and,

Z is a polar group selected from the group consisting of hydroxy, alkoxy, C-carboxy, carbonyl, nitro, cyano, amino, ammonium, -$NR^{11}R^{12}$, C-amido, S-sulfonamido, sulfinyl, sulfonyl, phosphonyl, ureido, amidino, guanidinyl, morpholino, piperidinyl and tetrazolo.

4. The compound of claim 1 wherein wherein R^3, R^4, R^5 and R^6 are independently selected from the group consisting of:

hydrogen;

halo;

unsubstituted lower alkyl;

lower alkyl substituted with one or more groups selected from the group consisting of:

hydroxy;

halo;

C-carboxy substituted with a group selected from the group consisting of:

hydrogen; or,

unsubstituted lower alkyl;

amino; or,

-$NR^{11}R^{12}$;

unsubstituted lower alkyl alkoxy;

lower alkyl alkoxy substituted with one or more halo groups;

unsubstituted aryloxy;

aryloxy substituted with one or more groups indepedently selected from the group consisting of:

unsubstituted lower alkyl;

lower alkyl substituted with one or more halo groups;
hydroxy;
unsubstituted lower alkyl alkoxy;
halo;
amino; or,
$-NR^{11}R^{12}$;

S-sulfonamido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen and unsubstituted lower alkyl;
unsubstituted aryl;
aryl substituted with one or more groups independently selected from the group consisting of:
halo;
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
amino; or,
$-NR^{11}R^{12}$;

unsubstituted heteroaryl;
heteroaryl substituted with one or more groups independently selected from the group consisting of:
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
hydroxy;
halo;
amino; or,
$-NR^{11}R^{12}$;

unsubstituted heteroalicyclic;
heteroalicyclic substituted with one or more groups independently selected from the group consisting of:

halo;
hydroxy;
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
amino; or,
$R^{11}R^{12}$;
unsubstituted lower alkyl O-carboxy;
C-amido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl; and,
N-amido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl.

5. The compound of claim 3 wherein wherein R^3, R^4, R^5 and R^6 are selected from the group consisting of:
hydrogen;
halo;
unsubstituted lower alkyl;
lower alkyl substituted with one or more groups selected from the group consisting of:
hydroxy;
halo;
C-carboxy substituted with a group selected from the group consisting of:
hydrogen; or,
unsubstituted lower alkyl;
amino; or,
$-NR^{11}R^{12}$;

unsubstituted lower alkyl alkoxy;
lower alkyl alkoxy substituted with one or more halo groups;
unsubstituted aryloxy;
aryloxy substituted with one or more groups indepedently selected from the group consisting of:
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
hydroxy;
unsubstituted lower alkyl alkoxy;
halo;
amino; or,
$-NR^{11}R^{12}$;
S-sulfonamido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen and unsubstituted lower alkyl;
unsubstituted aryl;
aryl substituted with one or more groups independently selected from the group consisting of:
halo;
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
amino; or,
$-NR^{11}R^{12}$;
unsubstituted heteroaryl;
heteroaryl substituted with one or more groups independently selected from the group consisting of:
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
hydroxy;

halo;
amino; or,
$-NR^{11}R^{12}$;
unsubstituted heteroalicyclic;
heteroalicyclic substituted with one or more groups independently selected from the group consisting of:
halo;
hydroxy;
unsubstituted lower alkyl;
lower alkyl substituted with one or more halo groups;
unsubstituted lower alkyl alkoxy;
amino; or,
$R^{11}R^{12}$;
unsubstituted lower alkyl O-carboxy;
C-amido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl; and,
N-amido wherein R^{11} and R^{12} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and unsubstituted aryl.

6. The compound of claim 1, wherein:
R^1, R^2, R^3, R^4, R^5, R^6 and R^7 are hydrogen;
R^8 and R^{10} are methyl; and,
R^9 is $-(CH_2)(CH_2)C(=O)OH$.

7. A pharmaceutical composition, comprising:
said compound of claim 6; and,
a physiologically acceptable carrier or excipient.

8. The compound of claim 1, wherein:
R^1, R^2 and R^7 are hydrogen;
R^3, R^4, R^5 and R^6 are independently selected from the group consisting of:
hydrogen;
hydroxy;
halo;
unsubstituted lower alkyl;
lower alkyl substituted with a carboxyic acid;
unsubstituted lower alkoxy;
carboxylic acid;
unsubstituted aryl;
aryl substituted with one or more unsubstituted lower alkyl alkoxy; or,
morpholino;
R^8 is selected from the group consisting of hydrogen and unsubstituted lower alkyl;
R^9 is $-(CH_2)(CH_2)C(=O)OH$; and,
R^{10} is unsubstituted lower alkyl.

9. The compound of claim 2 wherein R^7 is selected from the group consisting of:
hydrogen,
unsubstituted lower alkyl, and,
lower alkyl substituted with a group selected from the group consisting of:
unsubstituted cycloalkyl,
unsubstituted aryl, and,
aryl substituted with a group selected from hydroxy, unsubstituted lower alkyl alkoxy and halo.

10. The compound of claim 2 wherein Z is selected from the group consisting of:

$-C(=O)NR^{13}R^{14}$ wherein R^{13} and R^{14} are independently selected from the group consisting of:

hydrogen,

unsubstituted lower alkyl,

lower alkyl substituted with a group selected from the group consisting of amino and $-NR^{11}R^{12}$,

unsubstituted aryl,

aryl substituted with one or more groups selected from the group consisting of halo, hydroxy, unsubstituted lower alkyl alkoxy and trihalomethyl,

unsubstituted heteroaryl,

unsubstituted heteroalicyclic, and,

combined, a five-member or a six-member unsubstituted heteroalicyclic, and,

$-NR^{11}R^{12}$, wherein,

R^{11} and R^{12} are independently selected from the group consisting of unsubstituted lower alkyl and, combined, a five-member or a six-member unsubstituted heteroalicyclic ring.

11. The compound of claim 1 wherein:

R^7 is selected from the group consisting of unsubstituted lower alkyl,

lower alkyl substituted with one or more groups selected from the group consisting of:

unsubstituted cycloalkyl,

unsubstituted aryl,

aryl substituted with one or more groups independently selected from the group consisting of halo and unsubstituted

lower alkyl alkoxy and unsubstituted lower alkyl carboxyalkyl, and,

Z is selected from the group consisting of unsubstituted C-carboxy and unsubstituted lower alkyl C-carboxy.

12. The compound of claim 1 wherein:

R^3 R^4, R^5, and R^6 are independently selected from the group consisting of

hydrogen,

halo,

unsubstituted lower alkyl,

lower alkyl substituted with one or more hydroxy groups,

unsubstituted lower alkoxy,

unsubstituted aryl,

aryl substituted with one or more unsubstituted lower alkoxy groups, and,

$S(O)_2NR^{11}R^{12}$,

R^5 is hydrogen,

R^6 is $-NR^{11}R^{12}$, and,

R^{11} and R^{12} are independently selected from the group consisting of hydrogen, unsubstituted lower alkyl and, combined, a five-member or a six-member unsubstituted heteroalicyclic ring.

13. A method for the modulation of the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound, salt or prodrug of claim 1.

14. The method of claim 13 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

15. A pharmaceutical composition, comprising:
a compound, salt or prodrug of claim 1; and,
a physiologically acceptable carrier or excipient.

16. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a compound, salt or prodrug of claim 1 to said organism.

17. The method of claim 16 comprising administering therapeutically effective amount of 3-[2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid to said organism.

18. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

19. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

20. The method of claim 16 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast

cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

21. The method of claim 16 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

22. The method of claim 16 wherein said organism is a human.

23. A compound from the group consisting of:

3-[5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Iodo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(5-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5,6-Dimethoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Chloro-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[4-(2-Carboxyethyl)-3-methyl-1*H*-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-carboxylic acid methyl ester

3-[4-(2-Carboxy-ethyl)-3-methyl-1*H*-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indole-5-carboxylic acid

3-[4-Methyl-5-(2-oxo-5-sulfamoyl-1,2-dihydroindol-3-ylidene-methyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(5-methylsulfamoyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-{3-[4-(2-Carboxy-ethyl)-3-methyl-1*H*-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1*H*-indol-5-yl}-propionic acid

3-[5-(5-Ethyl-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Iodo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[2,4-Dimethyl-5-(4-methyl-2-oxo-1,2-dihydroindol-3-ylidene-methyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[2,4-Dimethyl-5-(5-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Methoxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(6-Hydroxy-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid 3,5-dimethoxy-benzyl ester

3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1*H*-pyrrol-3-yl}-propionic acid

3-[5-(6-Bromo-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-{5-[6-(3-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1*H*-pyrrol-3-yl}-propionic acid

3-{5-[6-(3-Ethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1*H*-pyrrol-3-yl}-propionic acid

3-{5-[6-(3-Ethoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1*H*-pyrrol-3-yl}-propionic acid

3-[2,4-Dimethyl-5-(2-oxo-6-phenyl-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[4-Methyl-5-(2-oxo-6-phenyl-1,2-dihydro-indol3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-{5-[6-(4-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1*H*-pyrrol-3-yl}-propionic acid

3-{5-[6-(4-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1*H*-pyrrol-3-yl}-propionic acid

3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-4-methyl-1*H*-pyrrol-3-yl}-propionic acid

3-{5-[6-(2-Methoxy-phenyl)-2-oxo-1,2-dihydroindol-3-ylidenemethyl]-2,4-dimethyl-1*H*-pyrrol-3-yl}-propionic acid

3-[2,4-Dimethyl-5-(6-morpholin-4-yl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Chloro-4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-2,4-dimethyl-1*H*-pyrrol-3-yl]-propionic acid

3-[5-(5-Chloro-4-methyl-2-oxo-1,2-dihydroindol-3-ylidenemethyl)-4-methyl-1*H*-pyrrol-3-yl]-propionic acid

3-[2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1*H*-pyrrol-3-yl]-propionic acid, sodium salt

24. A compound selected from the group consisting of:

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

5-Bromo-3-[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-phenyl-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(2-methoxyphenyl)-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(3-methoxyphenyl)-1,3-dihydroindol-2-one

3-[3,5-Dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

5-Bromo-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-phenyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(2-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(3-methoxyphenyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-(4-methoxyphenyl)-1,3-dihydroindol-2-one

5-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

6-Chloro-3-[4-(3-dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methoxy-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-6-methoxy-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-methyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-methyl-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-4-(2-hydroxyethyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid amide

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid isopropylamide

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-5-(morpholine-4-sulfonyl)-1,3-dihydroindol-2-one

3-[4-(3-Dimethylaminopropyl)-3,5-dimethyl-1H-pyrrol-2-ylmethylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide.